NO20023963D0 - Renset LH - Google Patents

Renset LH

Info

Publication number
NO20023963D0
NO20023963D0 NO20023963A NO20023963A NO20023963D0 NO 20023963 D0 NO20023963 D0 NO 20023963D0 NO 20023963 A NO20023963 A NO 20023963A NO 20023963 A NO20023963 A NO 20023963A NO 20023963 D0 NO20023963 D0 NO 20023963D0
Authority
NO
Norway
Prior art keywords
purification
ion
reverse phase
phase hplc
exchange chromatography
Prior art date
Application number
NO20023963A
Other languages
English (en)
Other versions
NO20023963L (no
NO328693B1 (no
Inventor
Gianfranco Paradisi
Mara Rossi
Laura Scaglia
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20023963L publication Critical patent/NO20023963L/no
Publication of NO20023963D0 publication Critical patent/NO20023963D0/no
Publication of NO328693B1 publication Critical patent/NO328693B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Semiconductor Lasers (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20023963A 2000-02-22 2002-08-20 Fremgangsmate for rensing av LH fra en prove, rekombinant LH med spesifikk aktivitet, anvendelse av rekombinant LH i fremstilling av medikamenter og farmasoytiske preparater omfattende rekombinante LH. NO328693B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00103692 2000-02-22
PCT/EP2001/000666 WO2001062774A2 (en) 2000-02-22 2001-01-22 Purified lh

Publications (3)

Publication Number Publication Date
NO20023963L NO20023963L (no) 2002-08-20
NO20023963D0 true NO20023963D0 (no) 2002-08-20
NO328693B1 NO328693B1 (no) 2010-04-26

Family

ID=8167926

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023963A NO328693B1 (no) 2000-02-22 2002-08-20 Fremgangsmate for rensing av LH fra en prove, rekombinant LH med spesifikk aktivitet, anvendelse av rekombinant LH i fremstilling av medikamenter og farmasoytiske preparater omfattende rekombinante LH.

Country Status (31)

Country Link
US (2) US7053054B2 (no)
EP (2) EP1261622B1 (no)
JP (1) JP4959898B2 (no)
KR (1) KR100808149B1 (no)
CN (1) CN100480258C (no)
AT (1) ATE356138T1 (no)
AU (1) AU780377B2 (no)
BG (1) BG65761B1 (no)
BR (2) BR122012018280B8 (no)
CA (1) CA2399100C (no)
CY (1) CY1108056T1 (no)
CZ (1) CZ303274B6 (no)
DE (1) DE60127100T2 (no)
DK (1) DK1261622T3 (no)
EA (1) EA004385B1 (no)
EE (1) EE04932B1 (no)
ES (1) ES2278722T3 (no)
HK (1) HK1052014A1 (no)
HR (1) HRP20020651B1 (no)
HU (1) HU227007B1 (no)
IL (2) IL151309A0 (no)
MX (1) MXPA02007867A (no)
NO (1) NO328693B1 (no)
PL (1) PL207728B1 (no)
PT (1) PT1261622E (no)
RS (1) RS50416B (no)
SI (1) SI1261622T1 (no)
SK (1) SK287041B6 (no)
UA (2) UA78676C2 (no)
WO (1) WO2001062774A2 (no)
ZA (1) ZA200206108B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78676C2 (en) * 2000-02-22 2007-04-25 Applied Research Systems Purified lh
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
DE602004030546D1 (de) * 2003-03-04 2011-01-27 Aspenbio Pharma Inc LH zur Verwendung der Erhaltung einer oder mehreren Schwangerschaften durch Induktion der Bildung des sekundären Gelbkörpers.
CN1283792C (zh) * 2003-11-14 2006-11-08 余伟明 生物大分子组分相分离法
CN100554277C (zh) * 2003-12-22 2009-10-28 阿雷斯贸易股份有限公司 Fsh的纯化方法
CA2582083A1 (en) * 2004-10-04 2006-04-20 Novetide, Ltd. A counterion exchange process for peptides
ATE408624T1 (de) * 2004-11-09 2008-10-15 Ares Trading Sa Verfahren zur reinigung von fsh
CN101282990B (zh) * 2005-08-26 2013-04-03 阿雷斯贸易股份有限公司 糖基化干扰素-β的制备方法
JP5199112B2 (ja) 2005-12-09 2013-05-15 アレス トレーディング ソシエテ アノニム Ｆｓｈ又はｆｓｈ変異体を精製するための方法
WO2009053360A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an fc-containing protein
AU2008314687A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying Fc-fusion proteins
CN101928342B (zh) * 2009-06-18 2013-05-08 上海天伟生物制药有限公司 一种高纯度绝经期促性腺素及其制备方法和用途
CN106999546A (zh) * 2014-05-01 2017-08-01 弗吉尼亚技术知识资产公司 角蛋白纳米材料及其制备方法
CN104569441B (zh) * 2015-01-19 2016-02-03 成都大熊猫繁育研究基地 大熊猫尿液促黄体素的酶联检测方法及其应用
BR112021022860A2 (pt) 2019-05-16 2022-01-18 Ceva Sante Animale Composições e métodos para aumentar o desempenho da reprodução em mamíferos não humanos com uso de hormônio luteinizante recombinante

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002757A1 (en) * 1988-09-02 1990-03-22 Integrated Genetics, Inc. Heteropolymeric protein
CA2053864C (en) 1989-02-21 2001-11-20 Irving Boime Modified forms of reproductive hormones
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
IT1287138B1 (it) * 1996-11-07 1998-08-04 Ibsa Inst Biochimique Sa Procedimento per la separazione e purificazione di fsh e lh
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
PT996629E (pt) 1997-06-25 2006-12-29 Applied Research Systems Análogos de hormonas glicoproteicas reticulados com ligações dissulfito, sua preparação e utilização
UA78676C2 (en) * 2000-02-22 2007-04-25 Applied Research Systems Purified lh

Also Published As

Publication number Publication date
CA2399100A1 (en) 2001-08-30
US7053054B2 (en) 2006-05-30
CN1404486A (zh) 2003-03-19
JP4959898B2 (ja) 2012-06-27
KR100808149B1 (ko) 2008-02-29
HUP0301814A2 (hu) 2003-08-28
HU227007B1 (en) 2010-04-28
BRPI0108553B8 (pt) 2021-05-25
UA92145C2 (en) 2010-10-11
DE60127100T2 (de) 2007-06-28
EA200200893A1 (ru) 2003-02-27
EE200200464A (et) 2003-12-15
EP1777231A3 (en) 2007-11-07
NO20023963L (no) 2002-08-20
DK1261622T3 (da) 2007-05-29
SK12052002A3 (sk) 2002-12-03
CZ20022856A3 (cs) 2003-01-15
ZA200206108B (en) 2003-07-31
JP2003532636A (ja) 2003-11-05
YU60302A (sh) 2005-09-19
BG65761B1 (bg) 2009-10-30
MXPA02007867A (es) 2003-02-10
US20030186893A1 (en) 2003-10-02
IL151309A0 (en) 2003-04-10
HRP20020651B1 (en) 2011-01-31
EE04932B1 (et) 2007-12-17
WO2001062774A2 (en) 2001-08-30
BR122012018280B8 (pt) 2021-05-25
EP1261622A2 (en) 2002-12-04
CN100480258C (zh) 2009-04-22
RS50416B (sr) 2009-12-31
BG107001A (bg) 2003-04-30
UA78676C2 (en) 2007-04-25
EP1777231A2 (en) 2007-04-25
NO328693B1 (no) 2010-04-26
ATE356138T1 (de) 2007-03-15
DE60127100D1 (de) 2007-04-19
SI1261622T1 (sl) 2007-06-30
CY1108056T1 (el) 2013-09-04
CZ303274B6 (cs) 2012-07-11
ES2278722T3 (es) 2007-08-16
BR0108553A (pt) 2003-12-23
WO2001062774A3 (en) 2002-03-14
EA004385B1 (ru) 2004-04-29
PL362891A1 (en) 2004-11-02
AU780377B2 (en) 2005-03-17
KR20030001358A (ko) 2003-01-06
BRPI0108553B1 (pt) 2016-06-14
IL151309A (en) 2010-11-30
HUP0301814A3 (en) 2004-10-28
EP1261622B1 (en) 2007-03-07
HRP20020651A2 (en) 2004-12-31
CA2399100C (en) 2011-11-08
SK287041B6 (sk) 2009-10-07
PT1261622E (pt) 2007-04-30
PL207728B1 (pl) 2011-01-31
AU3543601A (en) 2001-09-03
US20060079460A1 (en) 2006-04-13
HK1052014A1 (en) 2003-08-29
BR122012018280B1 (pt) 2018-01-09

Similar Documents

Publication Publication Date Title
NO20023963D0 (no) Renset LH
CY1108460T1 (el) Μεθοδος για τον καθαρισμο ανασυνδυασμενης hcg (ανθρωπινης χοριονικης γοναδοτροπινης) που εχει ειδικη βιοδραστικοτητα
DK0906122T3 (da) Aktiverede linkers og fremgangsmåde til at fremstille og oprense disse
MXPA01010522A (es) Composiciones de gonadotropina altamente purificada y procedimiento para prepararlas.
Hooper et al. Histone III: II. ISOLATION AND SEQUENCES OF CHYMOTRYPTIC PEPTIDES FROM CALF THYMUS HISTONE III

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

MK1K Patent expired